Adenocarcinoma of the Breast, Breast Cancer
Conditions
Keywords
CYCLOPHOSPHAMIDE (CYTOXAN), EPIRUBICIN, PEGFILGRASTIM, TAXOL (PACLITAXEL)
Brief summary
The purpose of this study is to give a drug regimen that is hoped to be effective in preventing cancer from coming back. Since it is an aggressive breast cancer, there is a moderate to high chance that the cancer may come back. The standard treatment for this tumor type includes a chemotherapy regimen with drugs named epirubicin (E) and cyclophosphamide (C) in a vein every 2 weeks for 4 treatments, followed by a drug named paclitaxel, every 2 weeks in your vein for 4 treatments. This study is an experimental study in which you will be given 6 cycles of EC followed by 6 cycles of paclitaxel. The purpose of getting 2 more cycles of EC and 2 more cycles of paclitaxel than what is normally given is to study a regimen that may be more effective than the current standard treatment in preventing the recurrence of this cancer. Specifically, in this study we are looking for side-effects and risks of these drugs as more cycles are given.
Interventions
DRUGepirubicin, cyclophosphamide, Paclitaxel,
EC (epirubicin 100 mg/m2, cyclophosphamide 600 mg/m2) q 14 days x 6 treatments with pegfilgrastim SQ day # 2 (6 mg). Paclitaxel (175 mg/m2) q 14 days x 6 treatments with pegfilgrastim SQ day # 2 (6 mg).
Sponsors
Amgen
Pfizer
Memorial Sloan Kettering Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have histologically confirmed adenocarcinoma of the breast confirmed at MSKCC or MSKCC satellites. Patients with breast cancer, regardless of tumor size or nodal status, are eligible for the study. Pathology will be assessed in the standard fashion (ie: HER-2/neu, estrogen receptor, and progesterone receptor status). Results of HER-2/neu, estrogen receptor, and progesterone receptor are not required for study entry. * Patients must be ≥18 years of age. * Patients must have an ECOG PS of 0 or 1. * If patients are offered chemotherapy postoperatively, then they must be within 84 days from the final surgical procedure required to treat the primary tumor(s). If patients are offered chemotherapy preoperatively, then they can receive treatment at anytime per MD's discretion. Patients may have bilateral synchronous breast tumors. * Patients may have received hormonal therapy for the purpose of chemoprevention but must be willing to discontinue prior to enrollment and while participating in this trial. * If patients have peripheral neuropathy, it must be \< than or equal grade 1. * Patients must be willing to discontinue sex hormonal therapy e.g., birth control pills, ovarian hormonal replacement therapy, etc., prior to enrollment. Women of childbearing potential must be willing to consent to using effective contraception while on treatment and for a reasonable period thereafter. * Absolute neutrophil count (ANC) ≥1000/µL and platelet count ≥100,000/µL. * Total Bilirubin must be within normal limits. Transaminases (SGOT and/or SGPT) may be up to 2.5 x institutional upper limit of normal (ULN) if alkaline phosphatase is \< than or equal to ULN, or alkaline phosphatase may be up to 4 x ULN if transaminases are \< than or equal to ULN. * Negative HCG pregnancy test for premenopausal women of reproductive capacity and for women less than 12 months after the menopause. * LVEF (by multi-gated radionuclide angiography or MUGA scan or by echocardiography)at or above institutional lower limit of normal * Patients must give written, informed consent indicating their understanding of and willingness to participate in the study.
Exclusion criteria
* Stage IV breast cancer * Chemotherapy, radiation therapy, immunotherapy, or biotherapy for current breast cancer. * Pregnant or lactating patients. * Patients with a concurrently active second malignancy, other than adequately treated nonmelanoma skin cancers or in situ cervical cancer. Patients with other non-mammary malignancies must have been disease-free for at least five years. * Patients with known allergy/hypersensitivity to doxorubicin, cyclophosphamide, paclitaxel (or other drugs formulated in Cremophor EL) or E. coli-derived proteins. * Patients with unstable angina, congestive heart failure, current use of digitalis, betablockers, or calcium blockers for therapy of congestive heart failure, arrhythmia requiring medical therapy, or with a history of a myocardial infarction within 12 months. * Patients with a psychiatric illness that would prevent them from understanding the nature of the investigational therapy and complying with protocol requirements. * Patients with concurrent medical conditions, which, in the judgment of the investigator, would make them inappropriate candidates for study enrollment. * Patients with active, unresolved infections.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the feasibility and safety of this dose-dense regimen. | conclusion of the study |
Countries
United States
Outcome results
None listed